Biosig Technologies (NASDAQ:STEX) Chairman Buys $49,980.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom bought 34,000 shares of Biosig Technologies stock in a transaction dated Thursday, May 28th. The shares were bought at an average price of $1.47 per share, for a total transaction of $49,980.00. Following the completion of the transaction, the chairman directly owned 309,000 shares of the company’s stock, valued at $454,230. This represents a 12.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 21st, Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies stock. The shares were bought at an average price of $1.04 per share, for a total transaction of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Price Performance

Shares of STEX stock opened at $1.51 on Friday. Biosig Technologies, Inc. has a 1 year low of $0.70 and a 1 year high of $14.11. The business’s 50 day moving average is $1.13. The firm has a market capitalization of $274.52 million, a price-to-earnings ratio of -0.16 and a beta of 1.58.

Biosig Technologies (NASDAQ:STEX) last announced its earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on STEX shares. Wall Street Zen lowered shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. Needham & Company LLC cut their price objective on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 21st. Finally, Weiss Ratings upgraded shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.